Rigel Pharmaceuticals, Inc. (RIGL)

Market Cap	147.84M
Revenue (ttm)	120.35M
Net Income (ttm)	-19.80M
Shares Out	17.56M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	140,679
Open	8.27
Previous Close	8.41
Day's Range	8.12 - 8.47
52-Week Range	7.12 - 17.30
Beta	1.04
Analysts	Buy
Price Target	5.81 (-31.0%)
Earnings Date	Jul 30, 2024

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 29, 2000
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: RIGL

Financial Performance

In 2023, RIGL's revenue was $116.88 million, a decrease of -2.79% compared to the previous year's $120.24 million. Losses were -$25.09 million, -57.16% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price forecast is $5.81, which is a decrease of -31.00% from the latest price.

Price Target

$5.81

(-31.00% downside)

Analyst Consensus: Buy